Publication of TroVax Phase II Analyses

RNS Number : 3083K
Oxford Biomedica PLC
29 July 2013
 

 

 

 

 

 

 

Oxford BioMedica Announces Publication of TroVax® Phase II Analyses in Peer-Reviewed Medical Journal 

 

-- Results from Phase II trial in prostate cancer published in Cancer Immunology, Immunotherapy --

 

-- Favourable tolerability and biomarker results --

 

Oxford, UK - 29 July 2013: Oxford BioMedica ("Oxford BioMedica" or "the Company") (LSE: OXB), the leading gene-based biopharmaceutical company, today announces that analyses of a TroVax® Phase II study in patients with castration-resistant prostate cancer (CRPC) have been accepted for publication in the peer-reviewed medical journal Cancer Immunology, Immunotherapy, the official journal of the Association for Cancer Immunotherapy.

 

TroVax® (MVA-5T4) is a therapeutic cancer vaccine designed to stimulate the immune system to destroy cancerous cells expressing the 5T4 tumour antigen, which is broadly distributed throughout a wide range of solid tumours.  The paper, entitled "Vaccination of castration-resistant prostate cancer patients with TroVax (MVA-5T4) in combination with docetaxel: a randomized phase II trial" will be published in Cancer Immunology, Immunotherapy later this year.  Previews of the clinical manuscript can be accessed online at: http://link.springer.com/article/10.1007%2Fs00262-013-1457-z.  

 

The randomised, open-label Phase II study in the United States aimed to assess the activity of TroVax® plus chemotherapy drug docetaxel (Taxotere®) versus docetaxel alone.  With an initial target enrolment of 80 patients, recruitment was challenging and the study enrolled 25 patients with metastatic CRPC; 12 were treated with TroVax® plus docetaxel and 13 were treated with docetaxel alone.  In October 2012, Oxford BioMedica made a strategic decision to close the US trial in order to focus on investigator-led Phase II studies.

 

Highlights from the Phase II CRPC study

·      TroVax® was well-tolerated in all patients.

·      Patients treated with TroVax® plus docetaxel showed a greater median progression-free survival of 9.67 months compared with 5.10 months for patients on the docetaxel alone arm (P = 0.097; HR = 0.31; 95 % CI 0.08-1.24)1.

·      Importantly, a pre-treatment biomarker previously demonstrated to predict 5T4 immune response and treatment benefit showed a strong association with 5T4 antibody response and a statistically significant association with progression-free survival in patients treated with TroVax® plus docetaxel, but not docetaxel alone.

·      The results demonstrate, for the first time, the prospective validation of a pre-treatment biomarker2 which is predictive of both 5T4 immune response and treatment benefit in cancer patients.

 

1.     P = p-value, HR = hazard ratio, CI = confidence interval.

2.     The biomarker is a combination of three pre-treatment blood parameters: 5T4 antibody levels; haemoglobin; and haematocrit (proportion of blood volume occupied by red blood cells) which can all be measured using a simple blood test. The biomarker is being used in ongoing investigator-led Phase II studies.

 

John Dawson, Chief Executive Officer of Oxford BioMedica, said: "Oxford BioMedica has a strong track record of publishing articles in well-respected medical journals. Peer-reviewed by experts, this paper demonstrates that our novel biomarker can identify patients most likely to benefit from treatment with TroVax®. The use of biomarkers in cancer immunotherapy is becoming increasingly important, which further underlines the attractiveness of TroVax® as a cancer vaccine."

 

-Ends-

 

For further information, please contact:


 

Oxford BioMedica plc:

Lara Mott, Head of Investor Relations and Corporate Communications

 

Tel: +44 (0)1865 783 000

 

Media Enquiries:

Mary-Jane Elliott/Matthew Neal

Consilium Strategic Communications

 

 

Tel: +44 (0)20 7920 2345

 

Notes to editors

 

1. About Oxford BioMedica®

Oxford BioMedica plc (LSE: OXB) is a biopharmaceutical company developing innovative gene-based medicines and therapeutic vaccines that aim to improve the lives of patients with high unmet medical needs. The Company's technology platform includes a highly efficient LentiVector® gene delivery system, which has specific advantages for targeting diseases of the central nervous system and the eye; and a unique tumour antigen (5T4), which is an ideal target for anti-cancer therapy. Through in-house and collaborative research, Oxford BioMedica has a broad pipeline with current partners and licensees including Sanofi, Pfizer, Novartis, GlaxoSmithKline, MolMed, Sigma-Aldrich, Biogen Idec, Emergent BioSolutions, ImaginAb and Immune Design Corp. Further information is available at www.oxfordbiomedica.co.uk and www.oxbsolutions.co.uk.

 

2. TroVax®

TroVax® is a therapeutic vaccine that stimulates the immune system to destroy cancerous cells expressing the 5T4 tumour antigen which is present on most solid tumours.  The product comprises a modified vaccinia virus Ankara (MVA) vector, encoding the 5T4 antigen.  Vaccinia viruses are commonly used as delivery systems for the development of antigen-specific vaccines.  Results from 10 previous clinical trials in colorectal, renal and prostate cancer have shown that TroVax® is safe and well tolerated in over 500 patients; can be administered in combination with various other treatments and show clear indication of efficacy.  Approximately 90% of patients treated with TroVax® mounted an anti-cancer immune response to the 5T4 antigen.


This information is provided by RNS
The company news service from the London Stock Exchange
 

END

 
 

NRAEAKXPAASDEFF